MYDECINE

Research & Development

Psychedelic Products Represent a New Frontier for Mental Health

The multi-billion-dollar market for Neurological Disorder Medicines will soon be disrupted amid a recent resurgence of the study into psychedelics and the data that is showing the immense benefits of these forms of medicine.

Facilitating the development of psilocybin-based treatments for the traumatized military population through our subsidiary NeuroPharm 

Integrated into Mydecine Innovations Group Inc Q2, 2020, NeuroPharm Inc. (NPI) is a Canadian, Veterans focused healthcare company developing a unique and proprietary set of pharmaceutical and natural health products addressing mental wellness in vulnerable populations including Veterans, EMS personnel and other high-risk constituencies. Using evidence-based medicine, NPI is developing a Psilocybin Dosing Technology and, in collaboration with its strategic partners, is establishing a therapeutic Psilocybin-based treatment to tackle the unmet needs of high-risk constituents.  

The NPI team is focused on the efficient development and clinical testing of break-through Psilocybin technologies. By leveraging strategic partnerships with global military institutions underpinned by industry, academia, scientific, medical, and clinical organizations, NPI is poised to bring to market much needed treatments in a cost-effective manner. NPI is deploying an intellectual property strategy through patent filings, copyrights, trademarks, and other protective measures. 

NPI is building tangible, durable competitive advantages as it secures a leadership role in treating meaningful unmet needs in a large, vulnerable population base.

← Back to homepage

Creating the future of psilocybin and fungi technology at our Innovation Center 

Our science team is working to build an ecosystem of resources targeted at unlocking the potential of fungi for human wellness. Through a combination of traditional medicine knowledge and modern scientific inquiry we strive to bring the public products that will aid them in their journey to personal wellness. Our R&D focus is on commercializing fungtional© mushroom and psilocybin-based products by analyzing the collections of molecules in fungi. Even in the most potent psychoactive mushrooms, psilocybin is only 1-2% of the total mass. This means that as much as 99% of that mushroom is composed of other molecules.  While many of those molecules may have no therapeutic value, some of them are pharmacologically active — either taken alone or in synergy with known psilocybin derivatives.

Our researchers will isolate and study all of the potentially “magic” molecules in mushrooms.  We are studying how these molecules work both alone and in combination with other molecules like THC and CBD. 

Formulating and commercializing psychedelic therapeutic treatments 

The currently accepted method of taking psilocybin (eating mushrooms) does not allow the user much control over the dose and is either illegal or decriminalized.  Current methods for administering psilocybin fail to provide reliable dosing, which makes the resulting effects both inconsistent and unreliable. Formulating the active components in “magic mushrooms” into reliable dosage forms will allow users to know exactly what they are taking. Formulated products will provide the desired active ingredients without any undesired compounds such as poisons and food-borne pathogens, such as bacteria or mold.

Our Research and Development Innovation Center 

Our laboratory in Denver Colorado will serve the needs for the study, selection and cultivation of valuable and rare fungal products and will incorporate state of the art analytical chemistry, molecular biology, next-gen sequencing, and tissue culture. We believe that the potential in fungi is known but more research is needed to bring it into market and that this lab will facilitate its efforts to bring the highest quality fungal food and wellness products to the public. The capabilities of our lab will serve as a cornerstone for Mydecine's research and development efforts.  

Applied Pharmaceutical Innovation Agreement with University of Alberta 

API is a not-for-profit commercial drug development institute that works in collaboration with the University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences as well as research and post-secondary institutions across Canada. API draws on an interdisciplinary network of over 30 pharmaceutical scientists, clinicians, regulatory, patent, and market experts in a variety of fields and disease areas to bring life-saving research to the real world. This agreement provides Mydecine with: 

  • Faster product development 
  • Ability to import, export, extract, analyze psychedelic drugs with full Government approval 
  • Access to a wide range of experts from discovery, pharmaceutical analysis, drug action, disposition, formulation, and clinical development.
  • Artificial intelligence capabilities to identify biosynthesis pathways for drug discovery, optimize targeted drug delivery systems and to design marketable drug compounds 

Ethica Clinical Research

Ethica CRO is a full-service Contract Research Organization (CRO) that conducts and manages ethical clinical research and is the only CRO approved by the Canadian Military. This leading research organization allows Mydecine to complete: 

  • Feasibility Assessments
  • Protocol Development
  • Study Start-up
  • Project Management
  • Study Monitoring
  • Regulatory Affairs
  • Medical Writing
  • Investigator Initiated Trials
View Timeline